| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adagrasib is a small molecule inhibitor of the KRAS G12C mutation, which is a common driver mutation in various types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer. Adagrasib — an orally bioavailable, covalent, allele-selective small-molecule inhibitor of KRAS G12C (also known as MRTX849; brand name KRAZATI) that irreversibly binds the mutant cysteine in the KRAS switch-II pocket to suppress downstream RAS–MAPK signaling in KRAS G12C–mutant tumors. It is a targeted anticancer drug (small-molecule covalent oncoprotein inhibitor) developed for KRAS G12C–driven malignancies, with FDA accelerated approval as monotherapy in previously treated KRAS G12C–mutated advanced NSCLC, and (more recently) an FDA accelerated approval for KRAS G12C–mutated metastatic/locally advanced colorectal cancer in combination with cetuximab (EGFR blockade) after standard chemotherapy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral dosing (commonly 600 mg twice daily in labeled settings). Clinically relevant systemic exposure is achievable, but GI intolerance and hepatotoxicity frequently drive dose interruptions/reductions. Notable PK/interaction constraints include CYP3A-mediated metabolism and clinically important drug–drug interaction potential (e.g., strong CYP3A modulators) plus exposure effects with acid-reducing agents; QT prolongation risk is an additional exposure-linked constraint. In-vitro vs systemic exposure relevance: Primary pharmacology is concentration- and target-occupancy–driven with on-target KRAS G12C covalent engagement; many pathway-level in-vitro effects occur at exposures that may not be uniformly achievable across tumors because of heterogeneity in drug delivery, efflux/uptake, and adaptive signaling. No external trigger is required. Clinical evidence status: Established clinical activity in KRAS G12C–mutated NSCLC after prior therapy (single-arm phase 2 registrational cohort supporting accelerated approval) with documented objective responses and intracranial activity in a subset; additional confirmatory/comparative and combination trials are ongoing. In KRAS G12C–mutated colorectal cancer, combination with cetuximab has clinically meaningful response rates supporting accelerated approval in later-line disease. Mechanism of Action: Adagrasib works by selectively inhibiting the activity of the KRAS G12C protein, which is a key player in the RAS/MAPK signaling pathway. By blocking the activity of KRAS G12C, adagrasib prevents the growth and proliferation of cancer cells, leading to tumor shrinkage and improved survival. Adagrasib is a promising treatment for patients with NSCLC and CRC who have the KRAS G12C mutation. Its ability to selectively inhibit KRAS G12C activity makes it a valuable option for patients who have limited treatment options. However, resistance to adagrasib can occur, and combination therapy may be necessary to overcome this resistance. Adagrasib is a novel KRAS G12C inhibitor that targets the mutant KRAS protein by covalently binding to its switch II pocket, thereby locking it in an inactive form. This inhibition blocks critical downstream signaling pathways, such as RAF/MEK/ERK and potentially PI3K/AKT/mTOR, which are essential for tumor growth and survival. Clinically, adagrasib is being developed and used primarily to treat NSCLC and other solid tumors with the KRAS G12C mutation, providing a targeted therapy option in a subset of cancers that historically have few effective targeted treatments. Adagrasib — mechanistic axis ranking for oncology relevance
|
| Source: |
| Type: |
| Cytochrome c ** The term "release of cytochrome c" ** an increase in level for the cytosol. Small hemeprotein found loosely associated with the inner membrane of the mitochondrion where it plays a critical role in cellular respiration. Cytochrome c is highly water-soluble, unlike other cytochromes. It is capable of undergoing oxidation and reduction as its iron atom converts between the ferrous and ferric forms, but does not bind oxygen. It also plays a major role in cell apoptosis. The term "release of cytochrome c" refers to a critical step in the process of programmed cell death, also known as apoptosis. In its new location—the cytosol—cytochrome c participates in the apoptotic signaling pathway by helping to form the apoptosome, which activates caspases that execute cell death. Cytochrome c is a small protein normally located in the mitochondrial intermembrane space. Its primary role in healthy cells is to participate in the electron transport chain, a process that helps produce energy (ATP) through oxidative phosphorylation. Mitochondrial outer membrane permeability leads to the release of cytochrome c from the mitochondria into the cytosol. The release of cytochrome c is a pivotal event in apoptosis where cytochrome c moves from the mitochondria to the cytosol, initiating a chain reaction that leads to programmed cell death. On the one hand, cytochrome c can promote cancer cell survival and proliferation by regulating the activity of various signaling pathways, such as the PI3K/AKT pathway. This can lead to increased cell growth and resistance to apoptosis, which are hallmarks of cancer. On the other hand, cytochrome c can also induce apoptosis in cancer cells by interacting with other proteins, such as Apaf-1 and caspase-9. This can lead to the activation of the intrinsic apoptotic pathway, which can result in the death of cancer cells. Overexpressed in Breast, Lung, Colon, and Prostrate. Underexpressed in Ovarian, and Pancreatic. |
| 1002- | SSE, | Osi, | Adag, | Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | H385 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:254 Target#:77 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid